The Novel Cardiovascular Therapeutics Summit reveals how the latest developments in the genetic and molecular understanding of cardiovascular disease, heart failure and cardiomyopathy are being translated into new pharmacological therapies in the clinic.
From the state of the art on cardiovascular drug development, to innovative therapeutic approaches, precision medicine and advancements in clinical trial methodologies, this meeting combines cutting edge science with a practical evaluation of case studies.
The agenda has been designed with insight from academicians and biopharmaceutical leaders in cardiovascular clinical research to help you tackle your major preclinical and clinical challenges to achieve safer, faster and more cost-effective cardiovascular drug development.
This is a great opportunity to interact with fellow peers in frank discussions that will ensure that you leave with the tools and ideas to advance your research and help shape the future of cardiovascular therapies.
Url:
Brochure: https://go.evvnt.com/80433-1
Prices:
Industry - Earlybird (Register by 27 January 2017): USD 2399
Industry - Standard: USD 2699
Academic - Earlybird (Register by 27 January 2017): USD 1399
Academic - Standard: USD 1599
Speakers: Matthew T Roe (DCRI), Joerg Koglin PhD (Merck), Brian A Ference (Wayne State University), Mark C Kowala PhD (Eli Lilly and Company)
Category: Conferences | Science, Health and Medicine | Cardiology
show less
From the state of the art on cardiovascular drug development, to innovative therapeutic approaches, precision medicine and advancements in clinical trial methodologies, this meeting combines cutting edge science with a practical evaluation of case studies.
The agenda has been designed with insight from academicians and biopharmaceutical leaders in cardiovascular clinical research to help you tackle your major preclinical and clinical challenges to achieve safer, faster and more cost-effective cardiovascular drug development.
This is a great opportunity to interact with fellow peers in frank discussions that will ensure that you leave with the tools and ideas to advance your research and help shape the future of cardiovascular therapies.
Url:
Brochure: https://go.evvnt.com/80433-1
Prices:
Industry - Earlybird (Register by 27 January 2017): USD 2399
Industry - Standard: USD 2699
Academic - Earlybird (Register by 27 January 2017): USD 1399
Academic - Standard: USD 1599
Speakers: Matthew T Roe (DCRI), Joerg Koglin PhD (Merck), Brian A Ference (Wayne State University), Mark C Kowala PhD (Eli Lilly and Company)
Category: Conferences | Science, Health and Medicine | Cardiology
The Novel Cardiovascular Therapeutics Summit reveals how the latest developments in the genetic and molecular understanding of cardiovascular disease, heart failure and cardiomyopathy are being translated into new pharmacological therapies in the clinic.
From the state of the art on cardiovascular drug development, to innovative therapeutic approaches, precision medicine and advancements in clinical trial methodologies, this meeting combines cutting edge science with a practical evaluation of case studies.
The agenda has been designed with insight from academicians and biopharmaceutical leaders in cardiovascular clinical research to help you tackle your major preclinical and clinical challenges to achieve safer, faster and more cost-effective cardiovascular drug development.
This is a great opportunity to interact with fellow peers in frank discussions that will ensure that you leave with the tools and ideas to advance your research and help shape the future of cardiovascular therapies.
Url:
Brochure: https://go.evvnt.com/80433-1
Prices:
Industry - Earlybird (Register by 27 January 2017): USD 2399
Industry - Standard: USD 2699
Academic - Earlybird (Register by 27 January 2017): USD 1399
Academic - Standard: USD 1599
Speakers: Matthew T Roe (DCRI), Joerg Koglin PhD (Merck), Brian A Ference (Wayne State University), Mark C Kowala PhD (Eli Lilly and Company)
Category: Conferences | Science, Health and Medicine | Cardiology
read more
From the state of the art on cardiovascular drug development, to innovative therapeutic approaches, precision medicine and advancements in clinical trial methodologies, this meeting combines cutting edge science with a practical evaluation of case studies.
The agenda has been designed with insight from academicians and biopharmaceutical leaders in cardiovascular clinical research to help you tackle your major preclinical and clinical challenges to achieve safer, faster and more cost-effective cardiovascular drug development.
This is a great opportunity to interact with fellow peers in frank discussions that will ensure that you leave with the tools and ideas to advance your research and help shape the future of cardiovascular therapies.
Url:
Brochure: https://go.evvnt.com/80433-1
Prices:
Industry - Earlybird (Register by 27 January 2017): USD 2399
Industry - Standard: USD 2699
Academic - Earlybird (Register by 27 January 2017): USD 1399
Academic - Standard: USD 1599
Speakers: Matthew T Roe (DCRI), Joerg Koglin PhD (Merck), Brian A Ference (Wayne State University), Mark C Kowala PhD (Eli Lilly and Company)
Category: Conferences | Science, Health and Medicine | Cardiology
show less
Date/Times:
2500 Mason St, San Francisco, CA 94133
The Best Events
Every Week in Your Inbox
From Our Sponsors
UPCOMING EVENTS
Great suggestion! We'll be in touch.
Event reviewed successfully.